These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19644233)

  • 1. Experimental conditions substantially influence botulinum toxin potency testing.
    Mander G; Fink K; Vey M
    Clin Neuropharmacol; 2009; 32(4):234; author reply 235. PubMed ID: 19644233
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of purification on the bioavailability of botulinum neurotoxin type A.
    Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
    Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats.
    Sakamoto T; Torii Y; Takahashi M; Ishida S; Goto Y; Nakano H; Harakawa T; Ginnaga A; Kozaki S; Kaji R
    Toxicon; 2009 Nov; 54(6):857-61. PubMed ID: 19559720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.
    Jones RG; Alsop TA; Hull R; Tierney R; Rigsby P; Holley J; Sesardic D
    Toxicon; 2006 Sep; 48(3):246-54. PubMed ID: 16870221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A.
    Hunt T; Clarke K
    Clin Neuropharmacol; 2009; 32(1):28-31. PubMed ID: 18978494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of botulinum neurotoxin-A activity in food by peptide cleavage assay.
    Rasooly R; Stanker LH; Carter JM; Do PM; Cheng LW; He X; Brandon DL
    Int J Food Microbiol; 2008 Aug; 126(1-2):135-9. PubMed ID: 18571757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-lethal bioassay for potency testing of therapeutic clostridial neurotoxins.
    Sesardic D; Ekong T; McLellan KH; Das RG
    Dev Biol Stand; 1996; 86():342. PubMed ID: 8785982
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved bioassays using a local effect, such as muscle paralysis, as an endpoint.
    Cevc G
    Toxicon; 2015 Jun; 99():89-94. PubMed ID: 25804992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model.
    Boldt GE; Eubanks LM; Janda KD
    Chem Commun (Camb); 2006 Aug; (29):3063-5. PubMed ID: 16855686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin.
    Sesardic D; McLellan K; Ekong TA; Das RG
    Pharmacol Toxicol; 1996 May; 78(5):283-8. PubMed ID: 8737961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternatives in testing of bacterial toxins and antitoxins.
    Sesardic D
    Dev Biol (Basel); 2002; 111():101-8. PubMed ID: 12678229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A.
    Masuyer G; Thiyagarajan N; James PL; Marks PM; Chaddock JA; Acharya KR
    Biochem Biophys Res Commun; 2009 Mar; 381(1):50-3. PubMed ID: 19351593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose standardization of botulinum toxin.
    Krack P; Deuschl G; Benecke R; Ceballos-Baumann AO; Marion MH; Oertel WH; Poewe W
    Mov Disord; 1998 Jul; 13(4):749-51. PubMed ID: 9686787
    [No Abstract]   [Full Text] [Related]  

  • 14. The botulinum toxin LD50 potency assay - another chapter, another mystery.
    Pickett A
    Altern Lab Anim; 2012 Sep; 40(4):221-3. PubMed ID: 23067303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations.
    Capková K; Hixon MS; McAllister LA; Janda KD
    Chem Commun (Camb); 2008 Aug; (30):3525-7. PubMed ID: 18654701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new reason to frown. Does Botox get into the brain? Troubling research contradicts earlier findings about the treatment.
    Begley S
    Newsweek; 2008 Apr; 151(16):45. PubMed ID: 18491789
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
    Wohlfarth K; Sycha T; Ranoux D; Naver H; Caird D
    Curr Med Res Opin; 2009 Jul; 25(7):1573-84. PubMed ID: 19463043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysport: pharmacological properties and factors that influence toxin action.
    Pickett A
    Toxicon; 2009 Oct; 54(5):683-9. PubMed ID: 19332087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease.
    Burnett JC; Wang C; Nuss JE; Nguyen TL; Hermone AR; Schmidt JJ; Gussio R; Wipf P; Bavari S
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5811-3. PubMed ID: 19703771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of experimental technique for analysis and interpretation of data from animal experiments: outliers and increased variability resulting from failure of intraperitoneal injection procedures.
    Gaines Das R; North D
    Lab Anim; 2007 Jul; 41(3):312-20. PubMed ID: 17640458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.